Amarin Corporation plc (AMRN)
-NasdaqGM 6.78 
0.14(2.02%) May 24, 4:00PM EDT|After Hours
:
6.80 0.02 (0.29%) May 24, 6:26PM EDT
| Prev Close: | 6.92 |
|---|
| Open: | 6.88 |
|---|
| Bid: | 6.50 x 5000 |
|---|
| Ask: | 6.89 x 100 |
|---|
| 1y Target Est: | 18.56 |
|---|
| Beta: | 0.91 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 6.74 - 6.90 |
|---|
| 52wk Range: | 6.34 - 15.96 |
|---|
| Volume: | 2,836,904 |
|---|
| Avg Vol (3m): | 3,651,890 |
|---|
| Market Cap: | 1.02B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- All Amarin Eyes On Sunday's Prescription Dataat Seeking Alpha(Fri, May 24)
- Merck Stock Is a Good Investment (According to Merck)at Motley Fool(Fri, May 24)
- Biotech Stock Mailbag: Amarin, MannKind, Palatinat TheStreet(Fri, May 24)
- Amarin Stays Rangebound, Prescriptions Stagnateat Seeking Alpha(Fri, May 24)
- These 2 Patents Could Mean Everything Or Nothingat Seeking Alpha(Wed, May 22)
- Amarin announces patent allowance related to combination of Vascepa, Statintheflyonthewall.com(Wed, May 22)
- Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin TherapyGlobeNewswire(Wed, May 22)
- Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)at TheStreet(Tue, May 21)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- Vascepa Data Should Make Amarin Longs Worriedat Seeking Alpha(Mon, May 20)
- Amarin: It's The Strategy, Not The Scienceat Seeking Alpha(Mon, May 20)
- AMARIN CORP PLC\UK FinancialsEDGAR Online Financials(Fri, May 17)
- A Disconnect Between Future Prospects of Drug Candidates Versus Where Share Price is Currently Trading: Portfolio Manager Finny Kuruvilla Discusses the Biotech and Pharmaceutical SectorsWall Street Transcript(Thu, May 16)
- Amarin & Celsion: Post-Earnings Roundupat Seeking Alpha(Wed, May 15)
- Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Groundat Seeking Alpha(Mon, May 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 445.42 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.45 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.06 |
|---|
Business Summary
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases.
View More